1. Home
  2. Abbvie Inc Patent Portfolio Statistics

Abbvie Inc Patent Portfolio Statistics


Abbvie Inc.

Abbvie Inc.`s Profile

This article summarizes the perfomance of the assignee
in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee
is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent
applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Abbvie Inc. look like?

Total Applications: 1731
Granted Patents: 1302
Grant Index 78.29 %
Abandoned/Rejected Applications: 361 (21.71%)
In-Process Applications: 66
Average Grant Time: 2.82 Years
Average Office Actions: 1.52

Which Technology Area Abbvie Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1626 Organic Chemistry 230
1624 Organic Chemistry 220
1625 Organic Chemistry 188
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 79
1622 Organic Chemistry 70

How many patents are Abbvie Inc. filing every year?

Year Total Applications
2022 0*
2021 12*
2020 33
2019 41
2018 62

*The drop in the number of applications filed in last two
years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Abbvie Inc in USPTO?

Publication number: US20220017624A1

Abstract:
The present disclosure provides anti-α4β7 antibodies that
bind human α4β7, their methods of making, and their uses to treat patients with HIV
infection.


Publication date: 2022-01-20
Applicant: Abbvie Inc
Inventors: Bixby Jacqueline


Publication number: US20210277137A1

Abstract:
The present disclosure provides novel anti-CD40 antibodies,
compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of
making and using the same.


Publication date: 2021-09-09
Applicant: Abbvie Inc
Inventors: Shiming Ye


Publication number: US20210275528A1

Abstract:
The present invention relates to the method of treating heavy
menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by
administering an effective amount of
4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric
acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and
progestogens.


Publication date: 2021-09-09
Applicant: Abbvie Inc
Inventors: Juki Ng Wing-Keung


How are Abbvie Inc’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17378565 Anti-Alpha-4-Beta-7 Antibodies OPAP Central, Docket
17327264 Anti-Cd40 Antibodies And Their Uses Application Undergoing Preexam Processing 1644
17325900 Methods Of Treating Heavy Menstrual Bleeding Docketed New Case – Ready for Examination OPAP Central, Docket
17295181 Methods Of Treating Acute Hcv Application Undergoing Preexam Processing 1629